Direct Nose-to-Brain Drug Delivery Technologies Market
完整報告名稱與涵蓋範圍
Direct Nose-to-Brain Drug Delivery Technologies Market Size, Share & Trends Analysis Report, By Technology (Upper Nasal Cavity Deposition Devices, Bi-Directional and Breath-Powered Devices, Mucoadhesive and Permeation-Enhancing Formulations, Nanocarrier and Particle-Based Formulations), By Molecule Type (Small Molecules, Peptides and Proteins, Nucleic Acids and Biologics), By Indication (Migraine and Acute Neurological Conditions, Psychiatric and Cognitive Disorders, Neurodegenerative Diseases, Seizure Emergencies and Other CNS Applications), By Development Stage, By Region, and Segment Forecasts, 2026-2035
報告摘要
The direct nose-to-brain drug delivery technologies market covers devices and formulations engineered to deliver drugs to the central nervous system via the olfactory and trigeminal pathways of the upper nasal cavity, including precision deposition and breath-powered devices, mucoadhesive and permeation-enhanced formulations, nanocarrier systems and the commercial and clinical-stage products built on them. Conventional nasal sprays that rely on systemic absorption are covered in the broader nasal drug delivery study and excluded here. Commercial revenue comes from a small number of approved migraine and CNS products; further growth depends on clinical progression of platform-based programs, which the forecast models explicitly.
The approach is pursued because it offers rapid onset and partial bypass of the blood-brain barrier for neurological and psychiatric conditions where oral and injectable routes are slow, invasive or limited. Approved precision-deposition migraine therapy and bi-directional nasal products have validated the device concept, while clinical programs test intranasal oxytocin, insulin, peptides and nanoparticle-carried molecules in cognitive, psychiatric and neurodegenerative indications. Quantifying true brain exposure in humans, achieving reproducible upper-cavity deposition and formulating larger molecules remain the scientific challenges that gate the field.
North America and Europe dominate development, with Japan and Israel contributing device and formulation innovators. Competition involves specialty device-drug companies, nasal device suppliers and formulation technology licensors.
The InsightAce study delivers revenue forecasts in US$ across all technology, molecule type, indication and development stage and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Direct Nose-to-Brain Drug Delivery Technologies Market Snapshot
Chapter 4. Global Direct Nose-to-Brain Drug Delivery Technologies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. Technology & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
5.2.1. Upper Nasal Cavity Deposition Devices
5.2.2. Bi-Directional and Breath-Powered Devices
5.2.3. Mucoadhesive and Permeation-Enhancing Formulations
5.2.4. Nanocarrier and Particle-Based Formulations
Chapter 6. Market Segmentation 2: By Molecule Type Estimates & Trend Analysis
6.1. Molecule Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
6.2.1. Small Molecules
6.2.2. Peptides and Proteins
6.2.3. Nucleic Acids and Biologics
Chapter 7. Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. Indication & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
7.2.1. Migraine and Acute Neurological Conditions
7.2.2. Psychiatric and Cognitive Disorders
7.2.3. Neurodegenerative Diseases
7.2.4. Seizure Emergencies and Other CNS Applications
Chapter 8. Market Segmentation 4: By Development Stage Estimates & Trend Analysis
8.1. Development Stage & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
8.2.1. Commercial Products
8.2.2. Clinical-Stage Programs
8.2.3. Preclinical and Platform Licensing
Chapter 9. Direct Nose-to-Brain Drug Delivery Technologies Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Impel Pharmaceuticals (Vectura Fertin Pharma)
11.2. OptiNose, Inc.
11.3. Kurve Technology, Inc.
11.4. Nasus Pharma Ltd.
11.5. Aptar Pharma
11.6. Neurelis, Inc.
11.7. Satsuma Pharmaceuticals (Shin Nippon Biomedical Laboratories)
11.8. Bioxcel Therapeutics, Inc.
11.9. Cyrano Therapeutics, Inc.
11.10. Seelos Therapeutics, Inc.
11.11. Recipharm AB
11.12. Aegis Therapeutics (Neurelis)
11.13. Lyndra Therapeutics, Inc.
11.14. Impel Neuropharma Legacy Programs
11.15. Nanomerics Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Direct Nose-to-Brain Drug Delivery Technologies Market Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 1. Global Direct Nose-to-Brain Drug Delivery Technologies Market Segmentation and Scope Overview
Table 2. Global Direct Nose-to-Brain Drug Delivery Technologies Market Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 2. Global Direct Nose-to-Brain Drug Delivery Technologies Market Share by Technology, 2026 & 2035
Table 3. Global Direct Nose-to-Brain Drug Delivery Technologies Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 3. Nose-to-Brain Delivery Pathways and Device Deposition Targets
Table 4. Global Direct Nose-to-Brain Drug Delivery Technologies Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 4. Commercial and Clinical Nose-to-Brain Products by Indication and Technology
Table 5. Global Direct Nose-to-Brain Drug Delivery Technologies Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Direct Nose-to-Brain Drug Delivery Technologies Growth Opportunity Analysis
Table 6. North America Direct Nose-to-Brain Drug Delivery Technologies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Direct Nose-to-Brain Drug Delivery Technologies Market Participants
Table 7. Europe Direct Nose-to-Brain Drug Delivery Technologies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Direct Nose-to-Brain Drug Delivery Technologies Market
Table 8. Asia Pacific Direct Nose-to-Brain Drug Delivery Technologies Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Evidence Standards for Demonstrating Direct Brain Exposure in Human Studies
Table 9. Strategic Developments of Leading Direct Nose-to-Brain Drug Delivery Technologies Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們